Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Immunovant is a clinical-stage biopharmaceutical company developing batoclimab, a subcutaneous anti-FcRn antibody, for autoimmune diseases. The company's lead programs target myasthenia gravis (MG), thyroid eye disease (TED), and Graves' disease, with pivotal trials ongoing or recently completed as of February 2026. Immunovant is majority-owned by Roivant Sciences and operates with a capital-efficient model focused on advancing batoclimab through regulatory approval.
Immunovant is developing batoclimab as a best-in-class FcRn antagonist with differentiated subcutaneous delivery and dosing convenience versus IV competitors. The company targets large autoimmune markets: MG (~85,000 US patients, $2B+ market), TED (~16,000 active moderate-to-severe cases annually), and Graves' disease (~1M US patients). Pricing power will derive from clinical differentiation versus Argenx's efgartigimod and Janssen's nipocalimab, with expected annual treatment costs in the $200,000-$400,000 range for severe indications. The Roivant affiliation provides operational infrastructure and reduces cash burn versus standalone biotechs.
Batoclimab Phase 3 trial readouts in myasthenia gravis (ASCEND-MG study) and thyroid eye disease
FDA regulatory submissions and approval timelines for lead indications
Clinical differentiation data versus Argenx efgartigimod and Janssen nipocalimab on efficacy, dosing frequency, and safety
Partnership announcements for ex-US commercialization rights
Cash runway updates and financing events given $400M annual burn rate
FDA approval risk for batoclimab in lead indications - Phase 3 trial failure or regulatory rejection would eliminate near-term value given single-asset focus
Competitive displacement risk from Argenx (efgartigimod already approved for MG), Janssen (nipocalimab in Phase 3), and UCB (rozanolixizumab approved) in FcRn antagonist space
Pricing and reimbursement pressure from payers given multiple FcRn therapies entering market simultaneously, potentially commoditizing the mechanism
Argenx first-mover advantage in MG with established commercial infrastructure and physician relationships - batoclimab must demonstrate clear superiority to gain share
Janssen's nipocalimab backed by J&J's commercial scale and broader indication pipeline including pregnancy-related conditions
Subcutaneous delivery advantage may erode as competitors develop improved formulations or alternative delivery methods
Cash runway extends approximately 7 quarters at current $400M annual burn rate - requires successful financing or partnership before late 2027
Equity dilution risk from future capital raises given pre-revenue status and ongoing trial costs
Roivant Sciences ownership concentration (majority stake) creates overhang risk if parent company liquidates position for portfolio management
low - Biopharmaceutical development timelines and regulatory processes are largely insulated from GDP fluctuations. Severe autoimmune disease treatment demand is non-discretionary. However, commercial launch success can be affected by healthcare spending trends and payer reimbursement policies during economic downturns.
Rising interest rates negatively impact valuation multiples for pre-revenue biotechs as future cash flows are discounted more heavily. Higher rates increase opportunity cost of capital for speculative growth investments, driving rotation from biotech to value sectors. Immunovant's $2.8B cash position (implied by 15.74x current ratio) generates higher interest income in rising rate environments, partially offsetting burn rate, but valuation compression dominates. Cost of capital for future financings increases materially.
minimal - Company maintains fortress balance sheet with no debt and 15.74x current ratio, indicating $2.8B+ in liquid assets against minimal current liabilities. No credit facility dependence. Future capital needs addressable through equity markets or strategic partnerships rather than debt financing.
growth - High-risk, high-reward clinical-stage biotech attracts growth investors and biotech specialists seeking binary event-driven returns. The 74.8% six-month return reflects momentum following positive clinical data or regulatory progress. Institutional healthcare funds and Roivant-affiliated investors dominate ownership. Not suitable for value or income investors given no revenue, negative cash flow, and binary approval risk.
high - Clinical-stage biotechs exhibit extreme volatility around trial readouts and regulatory decisions. Single-asset focus amplifies binary risk. The -65.8% ROE and -44.1% ROA reflect development-stage losses. Stock can move 30-50% on single data releases. Implied volatility typically 60-80% reflecting event risk premium.
